Expression of Epidermal Growth Factor Receptor Detected by Cetuximab Indicates Its Efficacy to Inhibit In Vitro and In Vivo Proliferation of Colorectal Cancer Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Shigeta, Kohei ^a   Hayashida, Tetsu ^a   Hoshino, Yoshinori ^a   Okabayashi, Koji ^a   Endo, Takashi ^a   Ishii, Yoshiyuki ^a   Hasegawa, Hirotoshi ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN A431; CELL STRAIN CACO 2; CELL STRAIN HCT116; CELL STRAIN SW480; CELL STRAIN WIDR; CELL SURFACE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT; ANIMAL; COLORECTAL TUMOR; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CETUXIMAB; COLORECTAL NEOPLASMS; HUMANS; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879188682     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066302     Document Type: Article

References (40)

1. Mendelsohn J, Baselga J, (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
2. Mellstedt H, (2003) Monoclonal antibodies in human cancer. Drugs Today (Barc) 39Suppl C: 1-16.
3. Yarden Y, (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37Suppl 4: S3-8.
4. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, et al. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53.
5. Olayioye MA, Neve RM, Lane HA, Hynes NE, (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167.
6. Scaltriti M, Baselga J, (2006) The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272.
7. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, et al. (2011) Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546.
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345.
9. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208.
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.
11. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
12. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
13. Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H, (2005) EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70: 1568-1578.
14. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286.
15. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, et al. (2004) Pharmacological background of EGFR targeting. Ann Oncol 15: 1007-1012.
16. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, et al. (2006) Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17: 855-857.
17. Wierzbicki R, Jonker DJ, Moore MJ, Berry SR, Loehrer PJ, et al. (2011) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 29: 167-174.
18. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810.
19. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, et al. (2012) Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-223.
20. Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, et al. (2009) Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 50: 123-131.
21. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, et al. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27: 1477-1484.
22. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
23. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, et al. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304: 1812-1820.
24. Matsuo T, Nishizuka SS, Ishida K, Iwaya T, Ikeda M, et al. (2011) Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models. BMC Res Notes 4: 140.
25. Gonzalez-Malerva L, Park J, Zou L, Hu Y, Moradpour Z, et al. (2011) High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A 108: 2058-2063.
26. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, et al. (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19: 508-515.
27. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169.
28. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA, (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90: 675-684.
29. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293-297.
30. Boughdady IS, Kinsella AR, Haboubi NY, Schofield PF, (1992) K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1: 275-282.
31. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA, (1993) Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 71: 3827-3838.
32. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
33. Zlobec I, Vuong T, Hayashi S, Haegert D, Tornillo L, et al. (2007) A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 96: 793-800.
34. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, et al. (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16: 102-108.
35. Goldstein NS, Armin M, (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331-1346.
36. Scartozzi M, Bearzi I, Mandolesi A, Pierantoni C, Loupakis F, et al. (2009) Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 9: 303.
37. Adams EJ, Green JA, Clark AH, Youngson JH, (1999) Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 52: 75-77.
38. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, et al. (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4772-4778.
39. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, et al. (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319.
40. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.